Skye Bioscience receives second Nasdaq delisting notice for failing minimum equity requirement
SKYE sits 44% above its 52-week low of $0.566 on light trading volume (0.4× avg).
Summary
Skye Bioscience received a Nasdaq delisting notice for failing to meet the minimum stockholders' equity requirement, adding to its existing delisting threat for bid price.
Key Events · Corporate Governance and Compliance · SKYE
-
New Nasdaq Delisting Notice
Skye Bioscience received a notification from Nasdaq on May 13, 2026, stating it is not in compliance with Listing Rule 5450(b)(1)(A), which requires a minimum of $10,000,000 in stockholders' equity. The company reported $9,011,804 in stockholders' equity as of March 31, 2026.
-
Compliance Deadline
The company has 45 calendar days, until June 29, 2026, to submit a plan to regain compliance. If accepted, Nasdaq may grant an extension of up to 180 calendar days, until November 9, 2026.
-
Compounding Delisting Threats
This new notice follows a previous Nasdaq deficiency letter received on March 19, 2026, for failing to meet the minimum $1.00 bid price requirement. The company now faces two separate delisting threats.
-
Financial Distress Context
This notice comes after the company's Q1 2026 10-Q, filed on May 11, 2026, which reiterated a going concern warning and reported deepening losses and critical cash burn.
Analysis · SKYE · Life Sciences
This 8-K reveals a new, distinct Nasdaq delisting threat for Skye Bioscience, adding to its existing bid price deficiency. The company's stockholders' equity of $9.01 million falls below the Nasdaq Global Market's $10 million minimum. This compounds the severe financial distress highlighted in recent filings, including a going concern warning and critical cash burn. Failure to regain compliance could lead to delisting, significantly impacting liquidity and investor confidence.
How filings like this one have moved
In the 30 days to Aug 27, 2026, 42.8% of the 995 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.07%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SKYE was trading at $0.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $28.6M. The 52-week trading range was $0.57 to $5.75. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.